Ironwood Pharmaceuticals (NASDAQ:IRWD) Receives "Hold" Rating from Jefferies Financial Group

Jefferies Financial Group reiterated their hold rating on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD - Free Report) in a research report released on Tuesday, MarketBeat Ratings reports. They currently have a $0.70 price target on the biotechnology company's stock, down from their previous price target of $8.00.

A number of other equities analysts have also recently issued reports on IRWD. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 29th. JMP Securities dropped their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research report on Thursday, January 30th. Craig Hallum reduced their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, January 22nd. Citizens Jmp lowered Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 14th. Finally, Leerink Partners reduced their target price on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research report on Monday, April 14th. Eight equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $4.78.

Ironwood Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ IRWD traded down $0.03 during mid-day trading on Tuesday, hitting $0.73. 3,326,562 shares of the company were exchanged, compared to its average volume of 2,563,472. The stock has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $3.02. Ironwood Pharmaceuticals has a 1-year low of $0.59 and a 1-year high of $8.45. The firm has a market cap of $117.31 million, a price-to-earnings ratio of -24.17 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares of the company's stock, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares of the company's stock, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 192,381 shares of company stock valued at $338,591 over the last 90 days. Corporate insiders own 12.90% of the company's stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ironwood Pharmaceuticals in the 4th quarter valued at about $36,000. Journey Strategic Wealth LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $47,000. Envestnet Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth $50,000. Finally, Xponance Inc. acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at $50,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.